Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 2/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127933 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL4127935 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL19336874 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL7323358 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL4112859 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL4112861 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL25662275 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL4112857 | 0.79 | CA1 (0.46) | CA1CA2CA4PTGS1PTGS2 | |
| SCHEMBL9803788 | 0.77 | — | — | |
| SCHEMBL17294254 | 0.77 | CA1 (0.45) | CA1CA2CA4PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | CA1 4788/4885CA2 4859/4885CA4 4427/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CA1 4799/4885CA2 4866/4885CA4 4547/4885 |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NT5C | CA1 4780/4885CA2 4861/4885CA4 4491/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CA1 4799/4885CA2 4866/4885CA4 4547/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CA1 4799/4885CA2 4866/4885CA4 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.